HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RHEI to distribute Drs. Hans Schreuder in Asia

This article was originally published in The Rose Sheet

Executive Summary

RHEI Pharmaceuticals has licensed Drs. Hans Schreuder Vision for Health Skin Care line for marketing and distribution in Asia, according to Feb. 21 release. RHEI - a specialty pharmaceuticals company that focuses on marketing proprietary medicines in China - will distribute the line through its pharmacy division. "Professional skin care is one of the fastest-growing segments within the cosmetics and toiletries industry in China. With an increase in Chinese living standards, people are seeking more specialized products and appreciate a holistic approach to healthcare," says Dr. Hans Schreuder, president and founder of the line, which consists of seven skin-nutritious products - including a scar treatment, facial cleansing lotion and anti-aging morning and night creams - featuring natural ingredients such as vitamin E, oatmeal, yeast, lactic acid and soy...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS015265

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel